The NIDO-361 clinical drug trial into a treatment for Kennedy Disease is now underway. NIDO-361 is a gene modification drug and it is at the cutting edge of new research into treatments for Kennedy Disease.
Please note that KD-UK has been advised that all the places for participants for the first phase of the UK trial have now been allocated.
The clinical trial directly follows a natural history study sponsored by NIDO, where KD patients were followed with muscle MRIs for a year in the UK, US and Japan in order to identify better ways to define disease progression.
The current trial has specific inclusion criteria. If you are already in the National Register, or are being followed by the clinic in London, the team already has data regarding your potential eligibility and may contact you about the trial if further participants are needed.